Goldman Sachs raised the firm’s price target on Mirion (MIR) to $16 from $13 and keeps a Buy rating on the shares after its Q3 results. The company’s Q3 adjusted EBITDA missed expectations as stronger margins in Technologies were offset by softer Medical performance and higher Corporate expense, the analyst tells investors in a research note. The firm adds however that the guide appears achievable, buoyed by momentum in Nuclear new build, further noting that the company’s December 3rd investor day is timely and could act as a positive catalyst for the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MIR:
- Mirion reports Q3 adjusted EPS 8c, consensus 9c
- Mirion still sees FY24 adjusted EPS 37c-42c, consensus 39c
- MIR Earnings this Week: How Will it Perform?
- Mirion initiated with a Buy at B. Riley
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
